Evaluation of the safety and efficacy of platelet rich plasma in treatment of patients with chronic telogen effluvium

Evaluation of the safety and efficacy of platelet rich plasma in treatment of patients with chronic telogen effluvium: a randomized controlled, patient blind, evaluator blind, clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202006539654415

Enrollment

Registered

2020-06-08

Start date

2018-03-12

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Intradermal injection of scalp

Intradermal injection of scalp using special platelet rich plasma tubes Group 1

Intradermal injection of PRP using ordinary laboratory tubes. Group 2

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: female patients chronic telogen effluvium patients (diffuse hair falling more than 6 months) aged between 18 and 55 years

Exclusion criteria

Exclusion criteria: ? Pregnant and lactating women. ? Patients having any dermatological diseases affecting the scalp. ? Thyroid dysfunction. ? Chronic medical diseases. ? Patients with anemia (hemoglobin level <10mg/dl), thrombocytopenia (platelet count < 100,000 /µL), coagulopathies or patients on anticoagulant therapy as aspirin and patients with iron deficiency. ? Patients received topical or systemic treatment for hair loss in the last three months before the study.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale (VAS) It helps to measure hair shedding which was scored on a scale of 1-6. Patients were asked to look at the scale and point to the photograph that best describes the amount of hair shed on an average day. Grades 1-3 were considered normal, Grade 4 was borderline, while Grades 5& 6 indicated excessive shedding;Hair pull test (HPT): A bundle of hair was grasped between the thumb, index and middle finger from the base near the scalp, and firmly & slowly pulled. The extracted hairs were counted.;Trichoscopy, The trichoscope used was (Micro-viewer 1.3 MP, Made in China), using lens (x200) magnification. 3 trichoscopic photos were taken from each of the frontal, temporal areas and vertex. It measured hair density (number of hairs/cm2), and hair thickness (mean/mm).;Safety evaluation : safety was evaluated by monitoring any local side effects like (pain, itching, erythema, ecchymosis, headache and tightness ) or systemic side effects which were reported either by the patients and / or the physician.	—

Measure

Time frame

Visual analogue scale (VAS) It helps to measure hair shedding which was scored on a scale of 1-6. Patients were asked to look at the scale and point to the photograph that best describes the amount of hair shed on an average day. Grades 1-3 were considered normal, Grade 4 was borderline, while Grades 5& 6 indicated excessive shedding;Hair pull test (HPT): A bundle of hair was grasped between the thumb, index and middle finger from the base near the scalp, and firmly & slowly pulled. The extracted hairs were counted.;Trichoscopy, The trichoscope used was (Micro-viewer 1.3 MP, Made in China), using lens (x200) magnification. 3 trichoscopic photos were taken from each of the frontal, temporal areas and vertex. It measured hair density (number of hairs/cm2), and hair thickness (mean/mm).;Safety evaluation : safety was evaluated by monitoring any local side effects like (pain, itching, erythema, ecchymosis, headache and tightness ) or systemic side effects which were reported either by the patients and / or the physician.

—

Secondary

Measure	Time frame
Comparison of platelet concentration at the PRP, between the special PRP tubes and the ordinary laboratory tube;Patient satisfaction, a 5-items questionnaire form was filled by patients to evaluate their satisfaction about the treatment	—

Countries

Egypt

Contacts

Public ContactAmr Abdelhamed

Lecturer Medical doctorate

dramr80@yahoo.com00201005825574

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026